Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1959 1
1960 2
1961 2
1962 3
1963 3
1964 9
1965 5
1966 7
1967 7
1968 7
1969 10
1970 9
1971 5
1972 7
1973 1
1974 6
1975 4
1976 3
1977 3
1978 6
1979 9
1980 10
1981 16
1982 13
1983 12
1984 17
1985 23
1986 27
1987 29
1988 30
1989 26
1990 23
1991 22
1992 28
1993 35
1994 14
1995 23
1996 37
1997 20
1998 50
1999 44
2000 45
2001 52
2002 60
2003 45
2004 69
2005 73
2006 51
2007 65
2008 93
2009 86
2010 78
2011 99
2012 104
2013 91
2014 79
2015 82
2016 78
2017 62
2018 76
2019 76
2020 64
2021 56
2022 64
2023 77
2024 93
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,211 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, Watanabe A, Ito M, Tajima Y, Matsuyama H, Uemura H. Miyake H, et al. Eur Urol Oncol. 2024 Jun;7(3):625-632. doi: 10.1016/j.euo.2023.12.013. Epub 2024 Jan 30. Eur Urol Oncol. 2024. PMID: 38296736 Free article.
New year's greetings 30-1.
Miyake H. Miyake H. Int J Urol. 2023 Jan;30(1):5. doi: 10.1111/iju.15121. Int J Urol. 2023. PMID: 36702786 No abstract available.
[Cabazitaxel].
Harada K, Miyake H, Fujisawa M. Harada K, et al. Among authors: miyake h. Nihon Rinsho. 2016 May 20;74 Suppl 3:640-3. Nihon Rinsho. 2016. PMID: 27344808 Japanese. No abstract available.
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T. Sazuka T, et al. Among authors: miyake h. Sci Rep. 2023 Nov 23;13(1):20629. doi: 10.1038/s41598-023-48087-4. Sci Rep. 2023. PMID: 37996622 Free PMC article.
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Oya M, Albiges L, Aizawa M, Umeyama Y, Wang J, di Pietro A, Schmidinger M. Tomita Y, et al. Among authors: miyake h. ESMO Open. 2023 Dec;8(6):102034. doi: 10.1016/j.esmoop.2023.102034. Epub 2023 Oct 20. ESMO Open. 2023. PMID: 37866029 Free PMC article.
Masticatory function and cognitive function.
Kubo KY, Ichihashi Y, Kurata C, Iinuma M, Mori D, Katayama T, Miyake H, Fujiwara S, Tamura Y. Kubo KY, et al. Among authors: miyake h. Okajimas Folia Anat Jpn. 2010 Nov;87(3):135-40. doi: 10.2535/ofaj.87.135. Okajimas Folia Anat Jpn. 2010. PMID: 21174943 Free article. Review.
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M. Tanegashima T, et al. Among authors: miyake h. J Immunol. 2024 Jul 1;213(1):23-28. doi: 10.4049/jimmunol.2300308. J Immunol. 2024. PMID: 38758119 Free PMC article.
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy.
Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Nakamura E, Kaneko T, Kitano G, Motoshima T, Shiraishi, Kira S, Murashima T, Hara H, Matsumura, Nishiyama N, Miyake H, Kitamura H, Uemura H. Fujita K, et al. Among authors: miyake h. World J Urol. 2024 Sep 26;42(1):536. doi: 10.1007/s00345-024-05252-2. World J Urol. 2024. PMID: 39325218
Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
Watanabe H, Nakane K, Takahara K, Naiki T, Yasui T, Shiroki R, Koie T, Miyake H. Watanabe H, et al. Among authors: miyake h. Int J Urol. 2024 Sep;31(9):986-993. doi: 10.1111/iju.15498. Epub 2024 May 19. Int J Urol. 2024. PMID: 38764245
2,211 results